RA Capital Management Slashes Alcobra Ltd (ADHD) Position After FDA Clinical Hold

Page 6 of 8 – SEC Filing

Item 4. Ownership:

Provide the following information regarding
the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount Beneficially Owned:

See the response(s) to Item 9 on the attached cover
page(s).

(b)

Percent of Class:

See the response(s) to Item 11 on the attached cover page(s).

(c) Number of shares as to which such person has:
  (i)

sole power to vote or to direct the vote:

See the response(s) to Item 5 on the attached cover page(s).

 
  (ii)

shared power to vote or to direct the vote

See the response(s) to Item 6 on the attached cover page(s).

 
  (iii)

sole power to dispose or to direct the disposition of

See the response(s) to Item 7 on the attached cover page(s).

 
  (iv)

shared power to dispose or to direct the disposition of

See the response(s) to Item 8 on the attached cover page(s).

Item 5. Ownership of Five Percent
or Less of a Class:

If this statement is being filed to report the fact that as
of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities,
check the following [X].

Item 6. Ownership
of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7. Identification and Classification
of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

Not applicable.

Item 8. Identification and Classification
of Members of the Group:

Not applicable.

Follow Arcturus Therapeutics Ltd. (NASDAQ:ARCT)